Jasper Therapeutics scheduled a special stockholder meeting for September 30, 2026. Investors will vote on a proposed reverse stock split. The board seeks authority to implement a ratio between 1-for-15 and 1-for-35.
This action follows a June 3, 2026, notice from Nasdaq. The company’s stock failed to meet the minimum $1.00 bid price requirement.
Shareholders will also vote to increase authorized common shares from 490 million to 675 million. This increase facilitates the conversion of preferred stock from the Kira Pharmaceuticals acquisition. The expansion also supports a related $132 million financing agreement.
These measures aim to maintain the company's Nasdaq listing. The proposals also provide resources for an expanded clinical portfolio.